AFT PHARMACEUTICALS LIMITED

Operating revenue for the year ending March 2023 increased by 20% to $156.6 million, with strong growth in all regions and market channels.
AFT declares a maiden dividend of 1.1 cents per share, with near-term revenue target of $200 million supported by product launches and commercialization efforts.
FY24 guidance for operating profit falls between $22 million to $24 million, not including $6 million of expected licensing income from Maxigesic IV's US launch in 2024.

2023-05-22 08:01:00

AFT Pharmaceuticals has received approval from the US Food and Drug Administration for a rapid release tablet form of Maxigesic to manage mild to moderate acute pain in the US.
The approval opens an analgesic market worth around US$7.16 billion to AFT and is expected to grow at 5.8% a year.
Maxigesic Oral Liquid for children has recently been approved in 12 European countries via the European Union's decentralized registration procedure.

2023-03-02 09:39:00

ASX Briefs...everything...in 3 bullet points